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Abstract: Myotonic dystrophy type 1 (DM1) is a genetic disorder characterized by muscle wasting, myotonia, cataracts, 
cardiac arrhythmia, hyperinsulinism and intellectual deficits, and is caused by expansion of a CTG repeat in the 3’UTR of 
the Dystrophia Myotonica-Protein Kinase (DMPK) gene. The DMPK transcripts containing expanded CUG repeats ac-
cumulate in nuclear foci and ultimately cause mis-splicing of secondary genes through the dysregulation of RNA-binding 
proteins including Muscleblind 1 (MBNL1) and CUG binding protein 1 (CUGBP1). Correction of mis-splicing of genes 
such as the Skeletal muscle-specific chloride channel 1 (CLCN1), Cardiac troponin T (TNNT2), Insulin receptor (INSR) 
and Sarcoplasmic/endoplasmic reticulum Ca
2+ ATPase 1 (SERCA1) may alleviate some of the symptoms of DM1; hence 
identification of small molecule modulators is an important step towards a therapy for DM1 patients. Here we describe the 
generation of immortalized myoblast cell lines derived from healthy (DMPK CTG5) and DM1 patient (DMPK CTG1000) 
fibroblasts by constitutive overexpression of human telomerase reverse transcriptase (hTERT) and inducible overexpres-
sion of the Myoblast determination factor (MYOD). MBNL1-containing nuclear foci, mis-splicing events and defective 
myotube differentiation defects characteristic of DM1 were observed in these cells. A CLCN1 luciferase minigene con-
struct (CLCN1-luc) was stably introduced to monitor intron 2 retention in the DM1 cellular context (a reported splicing 
defect in DM1). The assay was validated by performing a high-throughput screen (HTS) of ~13,000 low molecular weight 
compounds against the CLCN1-luc DM1 myoblast cell line, providing an ideal system for conducting HTS to better un-
derstand and treat DM1. 
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INTRODUCTION 
  Myotonic dystrophy (DM) is the most common form of 
muscular dystrophy observed in adults, and symptoms in-
clude delayed relaxation of skeletal muscles following vol-
untary contraction (myotonia), muscle wasting, cataracts, 
cardiac arrhythmia, insulin resistance, and cognitive impair-
ment [1]. 98% of DM cases result from autosomal dominant 
inheritance of a CTG trinucleotide repeat expansion in the 
3´UTR of the Dystrophia Myotonica-Protein Kinase 
(DMPK) gene [2, 3] and are classified as DM type 1 (DM1). 
There is a correlation between the number of DMPK 3´UTR 
CTG repeats, age of onset and disease severity, with mildly 
affected patients having as few as 50 repeats and more acute 
cases 1000 repeats [3-5]. Several mouse models expressing 
expanded CUG repeats (CUGexp) in the 3´UTR of unrelated 
mRNAs develop myotonia and myopathy [6], and DMPK 
knockout mice show only a subset of symptoms of DM1 [7]. 
Together this indicates that it is not loss of DMPK function 
that causes the phenotypes of DM1, but instead an RNA gain 
of function.  
 DMPK CUGexp transcripts form hairpin structures that are 
retained in nuclear foci in DM1 cells [8-10]. The majority of  
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symptoms associated with DM1 are thought to result from 
the aberrant splicing of downstream target genes [1]. Best 
studied are the dysregulation of the splicing factors MBNL1 
and CUGBP1, which either alone or in concert are sufficient 
to cause many of the splicing defects associated with DM1 
[11, 12]. MBNL1 is normally involved in promoting muscle 
differentiation via regulation of postnatal changes in skeletal 
muscle splicing patterns [11, 13]. In DM1, MBNL1 binds to 
and is sequestered into nuclear foci by the mutant DMPK 
transcripts [14, 15]. The effect of MBNL1 loss of function is 
reflected in Mbnl1 knockout mice that exhibit Skeletal mus-
cle-specific chloride channel 1 (Clcn1), Cardiac troponin T 
(Tnnt2) and Skeletal troponin T (Tnnt3) splicing abnormali-
ties characteristic of DM1 [16]. The importance of MBNL1 
function for maintenance of adult splicing patterns is high-
lighted by the fact that viral overexpression of Mbnl1 in 
skeletal muscle of a CUGexp mouse model promotes adult 
splicing patterns for Clcn1,  Tnnt3 and Sarcoplas-
mic/endoplasmic reticulum Ca
2+ ATPase 1  (Serca1) [17]. 
Conversely, the consequences of increased CUGBP1 stabil-
ity in DM1 are demonstrated in mice transgenic for human 
CUGBP1 in heart and skeletal muscle that show muscle de-
generation and a shift towards fetal splicing patterns of sev-
eral target genes [18]. Taken together this data suggests that 
identification of regulators of aberrant splicing of 
MBNL1/CUGBP1 target genes may aid in development of 
therapies targeting the underlying cause of DM1.  
  Patients suffering from DM1 have traditionally been lim-
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pain killers for myotonia, ventilators and pacemakers to im-
prove respiratory and cardiac function, and physical exercise 
to fight muscle wasting. However, since the molecular 
mechanisms of DM1 etiology have been unraveled, the goal 
of researchers has shifted to the identification of more spe-
cific therapies, for which there is an unmet medical need. 
Progress is being made with antisense oligonucleotides and 
morpholinos targeting splice sites of the MBNL1/CUGBP1 
target genes such as CLCN1 [19] or the CUGexp transcript 
[20, 21] in mouse models of DM1, but the exact mechanisms 
involved are still being elucidated, and delivery issues asso-
ciated with intramuscular or intravenous injection of such 
therapies are yet to be resolved [22]. Small molecule com-
pounds offer the advantage of oral formulation, and high-
throughput screening (HTS) can be automated to assay mil-
lions of chemical entities in a short amount of time, even for 
somewhat complex cellular systems. 
  The key to the development of successful drug candi-
dates from HTS hits depends largely upon the choice of the 
most relevant assay system for the given target [23]. Bio-
chemical assays have the advantage of testing for direct in-
teraction of chemicals with their target, however only cell-
based assays allow for interrogation of pathways when the 
precise molecular target is unknown [24]. Additional advan-
tages of cell-based assays are the ability to monitor off-target 
effects, cell permeability and toxicity of compounds in the 
same system as was used for the primary screen. Previous 
assays designed to identify inhibitors of specific splice en-
hancers [25] or ligands for CUGexp RNA [26] have been bio-
chemical in nature and thus required secondary cell-based 
assays to test such factors. Given that aberrant splicing 
events in DM1 are both tissue- and developmental stage-
specific in nature [11, 27], and that skeletal muscle is the 
predominantly affected tissue in DM1 patients, one of the 
best cell types in which to develop an assay for monitoring 
aberrant splicing is patient-derived myoblasts.  
  To that end, we have generated immortalized fibroblast 
and myoblast cell lines derived from healthy (DMPK CTG5) 
and DM1 (DMPK CTG1000) individuals, as a tool for devel-
oping HTS-compatible assays in the DM1 cellular context. 
We stably introduced a CLCN1 luciferase minigene con-
struct (CLCN1-luc) into these cells as a means of monitoring 
CLCN1 intron 2 retention. Aberrant inclusion of intron 2 and 
exon 7a in CLCN1 transcripts is thought to be the leading 
cause of myotonia in DM1 patients and mouse models [28, 
29], given that mutations in CLCN1 alone are associated 
with dominant and recessive myotonia [30, 31], and that 
transgenic mouse models with CUGexp in transcripts other 
than DMPK show similar patterns of CLCN1 mis-splicing 
and myotonia [28]. We have miniaturized the CLCN1-luc 
assay into 1536-well format and conducted a HTS of 
~13,000 small molecule compounds in triplicate, validating 
the DM1 patient-derived cell line and CLCN1-luc minigene 
reporter for use in larger screens to identify modulators of 
aberrant splicing and potential therapeutics for the treatment 
of DM1. 
MATERIALS AND METHODOLOGY 
Generation of Inducible MYOD Construct 
  The coding region of human MYOD was amplified from 
the MGC:8630 IMAGE:2961494 clone in pOTB7 backbone 
using PCR primers containing SrfI restriction sites (for-
ward:
5'CGCCAGCCCGGGCCCATGGAGCTACTGTCGC
CAC
3' and reverse:
5'  CGGCCAGCCCGGGCTCAGAG-
CACC
3') and Phusion™ high fidelity DNA polymerase 
(NEB) as per manufacturer’s instructions. Following over-
night digestion with SrfI restriction endonuclease (NEB) this 
PCR product was cloned into the SrfI sites of a pTRE-
rtTA3Zeo-SrfccdBSrf vector which was modified from the 
pTREautoR3 vector [32] (kindly provided by Dr. David 
Markusic) as follows. A Zeocin resistance gene cassette had 
flanking foot-and-mouth disease virus (FMDV) 2a peptide 
sequences added on either side (to allow for generation of a 
multigene vector) and was cloned in-frame with the tetracy-
cline responsive transactivator ( rtTA) gene. The 5
´ 2a se-
quence was designed to end with a SrfI restriction site. The 
counter-selectable suicide gene ccdB was cloned into the SrfI 
site, generating pTRE-rtTA3Zeo-SrfccdBSrf. The MYOD 
PCR product was cloned into the SrfI sites of pTRE-
rtTA3Zeo-SrfccdBSrf replacing the ccdB gene and generat-
ing the MYOD/pTREautoR3 vector, which has the polycis-
tronic open reading frame rtTA-2a-Zeo-2a-MYOD under 
control of the tetracycline responsive promoter (TRE). Cor-
rect orientation and reading frame were confirmed by se-
quencing.  
Generation of CLCN1-luc Construct  
  The genomic segment spanning exon 2 to exon 3 of hu-
man CLCN1 (3630-4670 bp of GI:89161213) was amplified 
by PCR using NEB Phusion polymerase and 200 ng male 
genomic DNA as template (Promega), generating a 1 kb 
product with NcoI restriction sites at both ends (forward: 
5´CTCTGCCATGGTTTATGGCCATCACAAAGAAC
3´ and 
reverse: 
5´GGTTAACCATGGCCTGAAGGCTTTTGGCA 
CTGAC
3´). This fragment was cloned into the NcoI site im-
mediately upstream of luciferase in the pGL3 promoter vec-
tor (Promega), and the ATG start codon of luciferase was 
mutated to TTG via single primer mutagenesis [33] using 
primer sequence 
5´AGCCTTCAGGCCTTGGAAGACGCC
3´. 
The CLCN1-luc construct was generated by sub-cloning the 
CLCN1-luc cassette into the pLenti6/V5-D-TOPO vector 
(Invitrogen) as per manufacturer’s instructions. Correct ori-
entation and reading frame were confirmed by sequencing.  
Virus Production 
  The pBabe-puro vector expressing the catalytic subunit 
of human Telomerase reverse transcriptase (hTERT) was a 
kind gift from Dr. Robert Weinberg [34]. Retrovirus express-
ing hTERT was produced by co-transfection with the pack-
aging vector pCL-10A1. 10 μg of each vector was trans-
fected into 5 x 10
6 293T cells in a 10 cm tissue culture dish 
(Greiner) using FuGENE™ 6 (Roche) as per manufacturer’s 
instructions. 24 h post-transfection cells were re-fed with 
growth media consisting of DMEM (Gibco
®) supplemented 
with 10% fetal bovine serum (Hyclone) and 1X antibiotic-
antimycotic (Gibco®). Viral supernatant was harvested and 
filtered through a 0.45 m filter (Millipore) 48 h post-
transfection. 
  Lentivirus expressing MYOD or CLCN1-luc was pro-
duced by co-transfection of 10 g MyoD/pTREautoR3 or 
CLCN1-luc/pLenti6/V5-D-TOPO DNA with RRE, REV and 
VSV-g packaging vectors (6.5 g, 2.5 g and 3.5 g, respec-HTS-Compatible Splicing Assay in DM1 Cells  Current Chemical Genomics, 2010, Volume 4    11 
tively) into 293Tcells, and viral supernatant was harvested as 
described above. 
Generation of Immortalized Myoblast and CLCN1-luc 
Cell Lines 
  Primary fibroblast cell lines GM00321 (DMPK CTG5) 
and GM04033 (DMPK CTG1000) were purchased from 
Coriell Institute for Medical Research and maintained in 
MEM alpha growth media (Gibco®) supplemented with 
15% fetal bovine serum (FBS) (Hyclone) and 1X antibiotic-
antimycotic (Gibco®). Cells were immortalized by viral in-
fection with supernatant expressing hTERT. Briefly, 1 x 10
6 
cells were seeded in a T75 tissue culture flask (Greiner) and 
the next day treated with 2 ml of viral supernatant for 6 h 
prior to supplementation with 10 ml growth media. 48 h 
post-infection media was replaced and supplemented with 1 
g/ml puromycin (Hyclone). Selection was maintained for 5 
days prior to cell expansion. Immortalized cell lines were 
subsequently infected with MYOD supernatant and selected 
for 14 days in growth media supplemented with 200 g/ml 
zeocin (Invitrogen) and 5 g/ml doxycycline (Sigma). The 
CLCN1-luc reporter gene was introduced by infection of 
hTERT positive, inducible MYOD positive cells with 
CLCN1-luc supernatant and selection for 5 days with 1 
g/ml blasticidin (Invitrogen). 
  Following recovery from selection, immortalized wild-
type and DM1 fibroblasts were differentiated into myoblasts 
upon treatment with 5 g/ml doxycycline (Sigma) for at least 
24 h, or into myotubes after 3-7 days growth in differentia-
tion media (DMEM supplemented with 2% horse serum 
(Hyclone) and 1X antibiotic-antimycotic (Gibco®)) contain-
ing 5 g/ml doxycycline. All cells were maintained in 37
oC 
incubators with 5% CO2. 
RT-PCR Analysis 
  Total RNA was extracted from ~200,000 cultured cells 
grown in Greiner 6-well tissue culture treated plates using 
Qiagen RNeasy mini kit columns and quantified using a 
NanoDrop 1000 spectrophotometer (Thermo Scientific). 200 
ng RNA was used as template for cDNA synthesis with ran-
dom primers and SuperScript® II reverse transcriptase (Invi-
trogen), as per manufacturer’s instructions. 1 l of the result-
ing cDNA was used as template for each RT-PCR with 
Platinum® Taq DNA polymerase (Invitrogen). The follow-
ing primers were used: hTERT-pBabe3´UTR forward - 
5'GAGGTGCAGAGCGACTACTC
3' and reverse - 
5'CACCC 
TAACTGACACACATTCC
3'; TNNT2 forward - 
5'ATAGAA 
GAGGTGGTGGAAGAGTAC
3' and reverse - 
5'GTCTCAGC 
CTCTGCTTCAGCATCC
3';  INSR forward - 
5'CCAAAGA 
CAGACTCTCAGAT
3' and reverse - 
5'AACATCGCCAAG 
GGACCTGC
3';  SERCA1 forward - 
5'GATGATCTTC 
AAGCTCCGGGC
3' and reverse - 
5'CAGCTCTGCCTGA 
AGATGTG
3'; CLCN1-luc forward - 
5´CTCTGCCATGGTTT 
ATGGCCATCACAAAGAAC
3´ and reverse - 
5´AGGGCGT 
ATCTCTTCATAGCCTTA
3´; GAPDH forward - 
5'TGCACC 
ACCAACTGCTTA
3' and reverse - 
5'GGATGCAGGG AT-
GATGTTC
3'. RT-PCR was performed for 35 cycles using 
standard PCR conditions, annealing temperature of 55
oC and 
extension time of 30-60 seconds. PCR products were visual-
ized by the addition of SYBR® Gold (Invitrogen) to samples 
prior to electrophoresis at 100 V using 2-3% agarose 
(Sigma) dissolved in Tris-acetate-EDTA buffer (Sigma) and 
density of bands quantified using Alpha Innotech’s Al-
phaEase© FC software, version 3.2.1 (values expressed as 
average ± SEM). 
Western Blotting 
  Total and cytoplasmic/nuclear cell extracts were prepared 
by lysing cells directly in 15 cm tissue culture dishes 
(Greiner) as per manufacturer’s instructions (Active Motif). 
Samples were quantified by addition of Coomassie Protein 
Assay Reagent (Pierce) and readout with a Molecular De-
vices SpectraMax Plus
384 plate reader at 595 nm. Protein 
samples (20-40 g per lane) were subjected to SDS-PAGE 
using NuPAGE® Novex Bis-Tris 4-12% gradient precast 
gels (Invitrogen), and subsequently transferred onto 0.45 μm 
nitrocellulose membrane (Invitrogen), as per manufacturer’s 
instructions. After incubation at room temperature with 
Blocker Casein in TBS (Pierce) for 1-2 h, membranes were 
incubated with antibody at 4
oC overnight (with shaking). 
Antibodies used were specific to MYOD (1:500 sc-760 – 
Santa Cruz), CLCN1 (1:1000 CLC11-A – Alpha Diagnos-
tic), CUG-BP1 (1:1000 05-621 – Upstate), MBNL1 (1:100 
ab49474 - abcam), LAMIN A/C (1:500 sc-20681 Santa 
Cruz), and -ACTIN (1:5000 A5316 – Sigma), and were 
diluted in blocking buffer supplemented with 0.1% Tween-
20 (Sigma). Following washing in Tris-buffered saline with 
Tween-20 (TBST) (Sigma), membranes were incubated with 
secondary antibodies conjugated with IRDye™800 (Rock-
land) or Alexa Fluor®680 dye (Invitrogen) for 1 h at room 
temperature (1:20,000 dilution in blocking buffer supple-
mented with 0.1% Tween-20), washed again with TBST and 
visualized (and protein expression quantified) using a LI-
COR Odyssey® infrared imaging system. Quantified protein 
levels are expressed as average ± SEM.  
In Situ Hybridization and Immunostaining 
  Method adapted from Mankodi et al. 2001 [35]. Cells 
were grown in 39 mm cell culture dishes with 20 mm cover-
glass insets (In vitro Scientific), fixed with 4% paraformal-
dehyde (PFA) (Electron Microscopy Sciences) at room tem-
perature for 20 minutes, washed in phosphate-buffered saline 
(PBS) (Sigma), and permeabilized by treatment with ice-cold 
2% acetone (Fisher Scientific) for 5 minutes. After PBS 
washing cells were pre-hybridized for 1 h at 45
oC in a wet 
chamber with distilled water using a buffer of 30% forma-
mide (Sigma) and 2X saline-sodium citrate buffer (SSC) 
(Sigma). Hybridization was then performed in a light-proof 
wet chamber for 2 h at 45
oC using the same buffer supple-
mented with 0.02% bovine serum albumin (BSA) (Sigma), 
66  μg/ ml yeast tRNA (Sigma), 2 mM sodium 
(meta)vanadate (Sigma) and 1 ng/μl RNase-free HPLC-
purified (CAG)7  2'  O-methyl RNA probe with a phos-
phorothioate backbone and 5' Alexa Fluor® 594 label (Inte-
grated DNA Technologies). Following hybridization cells 
were washed 3 x 10 minutes at 45
oC in a solution of 30% 
formamide and 2X SSC, then 3 x 10 minutes at room tem-
perature (with shaking) in a 1X SSC solution. MBNL1 im-
munostaining was then performed on these samples by 
blocking with a solution of 1% FBS and 1% BSA in PBS for 
1 h at room temperature and incubation with 2 μg/ ml pri-
mary antibody (in PBS) at 4
oC overnight (M3320 – Sigma). 
Antibody was washed off with 5 x 5 minute PBS washes and 
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body (Invitrogen) was added for 2 h at room temperature. 
Following 5 x 5 minute PBS washes, cells were incubated 
with 7 μg/ ml Hoechst 33342 (Invitrogen) in PBS for at least 
1 h at room temperature prior to imaging with a 60x/1.20W 
Olympus UPlanSApo objective on a Perkin Elmer Ultra-
VIEW VoX Confocal imaging system. 
  Immunostaining for Desmin (1:50 18-0016 - Invitrogen) 
and Myosin heavy chain (MHC) (1:250 18-0105 Invitrogen) 
was performed as for MBNL1 after fixation of cells in 24 
well plates (Greiner) in 2% PFA and permeabilization with 
0.25% Triton® X-100 in PBS for 5 minutes. In order to 
visualize cell morphology 20 μg/ml malachite green (Sigma) 
was added in parallel to Hoechst. Cells were imaged with a 
20x/0.40 Olympus LCPlanFI objective on a Perkin Elmer 
UltraVIEW VoX Confocal imaging system. 
CLCN1-luc Reporter Gene Assay and HTS 
  Stable CLCN1-luc DM1 or WT cells were plated at a 
density of 8000 cells/well in 50 μl for 384-well format or 
2000 cells/well in 6 μl for 1536-well format (in the presence 
of doxycycline) in tissue culture-treated Greiner custom 
white solid bottom plates using GNF Systems on-line screen-
ing equipment, incubated at 37
oC with 5% CO2 for 24 h prior 
to 500 nl (384-well) or 50 nl (1536-well) compound addition 
with a PinTool (GNF Systems) to give 1 % or 0.83% 
DMSO, respectively. Luciferase activity was then measured 
24 h post-compound addition by the addition of 30 μl (384-
well) or 3 μl (1536-well) Bright-Glo (Promega) and a 60 
second luminescence read with a Viewlux
TM CCD Imager 
(Perkin Elmer). For the HTS of ~13,000 compounds in trip-
licate, CLCN1-luc DM1 cells were treated as described 
above for 1536-well format such that the final compound 
concentration was 8.3 μM, and the AKT V inhibitor Tricirib-
ine (Calbiochem) was included on each assay plate as a posi-
tive control.  
RESULTS AND DISCUSSION 
Generation of Immortalized Myoblasts with Differentia-
tion Defects Characteristic of DM1 
  Given the complex nature of DM1 etiology in humans, 
and the fact that single gene transgenic and knockout mouse 
models of DM1 fail to recapitulate all symptoms of the hu-
man disease [6, 16, 18, 36-42], we chose to generate immor-
talized DM1 patient-derived cell lines in which to develop a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Generation of immortalized DM1 fibroblasts, myoblasts and myotubes. (A) RT-PCR confirmed hTERT expression in immortal-
ized WT and DM1 fibroblasts (hTERT FB), fibroblasts containing the MYOD expression construct before (MYOD FB) and after (Myoblast) 
doxycycline induction, and following serum starvation-induced differentiation (Myotube), but not in primary fibroblasts (Primary FB). Equal 
levels of cDNA template were confirmed by amplification of the GAPDH housekeeping gene. (B) Western blot analysis confirmed inducible 
expression of MYOD upon differentiation of immortalized WT and DM1 cell lines into myotubes. -actin protein expression was used to 
ensure equivalent amounts of total protein in each sample. (C) Immunostaining of immortalized WT and DM1 myoblasts and myotubes for 
markers of early (DESMIN) and late stage (MHC) differentiation (green), with malachite green counterstaining (red). Scale bars represent 
10μm. HTS-Compatible Splicing Assay in DM1 Cells  Current Chemical Genomics, 2010, Volume 4    13 
HTS-amenable assay. This would also allow for direct infer-
ence of assay results to the human disease condition, since 
signaling pathways are not always identical between mouse 
and human. Wildtype (WT) DMPK CTG5 and DM1 patient 
(DMPK CTG1000) fibroblast cells were immortalized follow-
ing introduction of constitutively overexpressed hTERT, 
which has previously been shown to allow human fibroblasts 
to proliferate for at least 36 population doublings [43]. RT-
PCR confirmed expression of hTERT in immortalized WT 
and DM1 cell lines carrying hTERT alone (hTERT FB) or 
hTERT and MYOD expression constructs (MYOD FB), and 
was maintained upon differentiation of these cells into 
myoblasts and myotubes with doxycycline treatment and 
serum starvation (Fig. 1A). Use of fibroblasts as a starting 
point allowed monitoring of myogenic differentiation defects 
in DM1 cells upon inducible overexpression of MYOD, the 
sole transcription factor necessary to convert fibroblast cells 
into myoblasts [44]. 
  As shown in Fig. (1B), MYOD protein expression was 
barely detectable by Western blot 24 h after treatment of 
immortalized fibroblasts with doxycycline (myoblasts), but 
was significantly increased upon differentiation of myoblasts 
into myotubes for 3-7 days. Upon quantification of Western 
blots across multiple experiments, DM1 myotubes were ob-
served to express between 63±4% of WT MYOD protein 
levels (relative to -actin housekeeping protein). A similar 
trend was observed by RT-PCR (data not shown). Decreased 
MYOD expression has previously been reported in cells 
overexpressing transcripts with a CUGexp [45], and more 
recently in muscle biopsy samples of DM1 patients [46]. As 
would be expected from reduced expression of MYOD, 
DM1 myoblasts showed limited capacity to differentiate 
down the myogenic lineage, as tested by immunostaining for 
the early myogenic marker Desmin [47] and late myogenic 
differentiation marker MHC [48], together with malachite 
green counterstaining for morphological changes in compari-
son to WT cells (Fig. 1C).  In vitro differentiation of 
myoblasts into myotubes is a highly variable, fluid process 
affected by cell density and growth conditions at the time of 
serum starvation, so variable morphology and stages of dif-
ferentiation are often observed within one culture. Overex-
pression of hTERT in these cell lines may have had some 
effect on the differentiation potential of WT and DM1 cells, 
as hTERT is usually down regulated during myoblast differ-
entiation [49]. However, since a significant distinction in 
differentiation potential (lack of Desmin expression) was 
reproducibly observed between WT and DM1 myoblasts 
prior to serum starvation, the immortalized DM1 cell lines 
were further characterized for their suitability to study aber-
rant splicing events.  
Immortalized Cell Lines Show MBNL1 Localization and 
Splicing Defects Characteristic of DM1 
  Immortalized WT and DM1 cell lines were analyzed by 
Western blot for expression of the splicing factors CUGBP1 
and MBNL1 (Fig. 2A). No significant difference in protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Splicing factor expression in immortalized DM1 cells. (A) Western blot analysis of CUGBP1 and MBNL1 splicing factor pro-
teins in immortalized WT and DM1 fibroblasts, myoblasts and myotubes (with Lamin A/C and -actin loading controls for nuclear and 
whole cell lysates, respectively). (B) Localization of DMPK mutant RNA to nuclear foci (highlighted by white arrowheads) via in situ hy-
bridization with a Texas Red-conjugated RNA probe containing 7 CUG repeats ((CUG)7-TR), together with MBNL1 immunostaining 
(green) and Hoechst counterstaining (blue). Scale bars represent 10μm. 14    Current Chemical Genomics, 2010, Volume 4  O’Leary et al. 
expression levels was observed between genotypes or 
throughout differentiation of the immortalized WT and DM1 
fibroblasts into myoblasts and myotubes. Altered cellular 
distribution, increased expression levels and hyperphos-
phorylation of CUGBP1 protein have been reported in some 
DM1 patients and mouse models [50, 51], however de-
creased CUGBP1 mRNA levels were reported in DM1 mus-
cle biopsies [52]. In addition, MBNL1 localization to nuclear 
foci containing CUGexp transcripts is a more definitive trait 
of DM1 cells [35, 53], so cells were further analyzed for 
MBNL1 cellular distribution. MBNL1 protein was found to 
co-localize with CUGexp transcripts in nuclear foci in immor-
talized DM1 myoblasts (Fig. 2B), as well as DM1 fibroblasts 
and myotubes (data not shown). Immunostaining revealed 
that MBNL1 protein was evenly distributed throughout the 
nuclei of WT cells (data not shown), however as previously 
described [14], the acetone treatment required for in situ hy-
bridization prevented visualization of this in the same ex-
periment.  
  The effect of MBNL1 mis-localization upon splicing of 
downstream target genes in immortalized DM1 cells was 
tested by RT-PCR using primers specific for three of the best 
characterized DM1 splicing defects in TNNT2, SERCA1 and 
INSR genes. These mis-splicing events are thought to con-
tribute to the cardiac arrhythmia and insulin resistance ob-
served in DM1 patients [1]. The splicing patterns observed in 
the WT and DM1 cell lines were as expected (Fig. 3A): exon 
5 was included in 91±1% and 92±1% of TNNT2 transcripts 
in DM1 myoblasts and myotubes, respectively (versus 55±2 
and 53±1% in WT counterparts); exon 11 was excluded in 
39±2% and 40±2% of INSR transcripts in DM1 fibroblasts 
and myoblasts, respectively (versus 14±1% and 17±1% in 
WT counterparts); exon 22 was excluded in 50±1% and 
68±2% of SERCA1 transcripts in DM1 myoblasts and myo-
tubes, respectively (versus 8±1% and 21±1% in WT coun-
terparts). Mis-splicing and expression loss of CLCN1 protein 
in skeletal muscle is associated with myotonia in DM1 pa-
tients and mouse models [28, 29]. Since CLCN1 mRNA ex-
pression in cultured myoblasts is  0.01% of that in mature 
muscle tissue [54], we tested for CLCN1 protein expression 
levels in our immortalized WT and DM1 cell lines by West-
ern blot (Fig. 3B). CLCN1 protein expression could only be 
detected in differentiated myotubes, and the expression level 
in DM1 myotubes was 43±1% of WT levels (determined 
across multiple experiments, relative to -actin loading con-
trol). This is consistent with previous findings in DM1 pa-
tient tissue and mouse models [28]. Therefore the immortal-
ized DM1 myoblast cell line was found to retain the aberrant 
splicing and expression loss of MBNL1/CUGBP1 target 
genes, and the myogenic differentiation defect associated 
with the disease. We proceeded to use this tool for develop-
ment of a HTS-compatible assay to monitor mis-splicing in 
DM1.  
CLCN1-luc Minigene Reporter Assay Validation  
    Myotonia is one of the most prevalent symptoms of 
DM1 [1, 55], and aberrant inclusion of intron 2 and exon 7a 
of the skeletal muscle-specific chloride channel gene CLCN1 
is associated with the myotonia observed in DM1 patients 
and mouse models [28, 29]. Therefore we chose to generate 
a luciferase minigene reporter construct spanning the ge-
nomic region of exon 2 to exon 3 of human CLCN1, driven 
by the CMV promoter of the pLenti6/V5-D-TOPO vector 
(Invitrogen). As shown by the schematic in Fig. (4A), the 
correct reading frame of the minigene was obtained upon 
removal of intron 2 during splicing in WT cells, however 
intron 2 retention in DM1 patient cells would lead to use of a 
premature stop codon and lack of luciferase expression. RT-
PCR analysis of WT and DM1 CLCN1-luc stable cell lines 
with primers spanning from CLCN1 exon 2 to the beginning 
of the luciferase coding region (Fig. 4B) demonstrated that 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). MBNL1/CUGBP1 target gene expression in immortalized DM1 cell lines. (A) RT-PCR analysis to detect splicing defects in 
MBNL1/CUGBP1 target genes using primers in flanking exons: TNNT2 exon 5 (E5) inclusion, INSR exon 11 (E11) exclusion and SERCA1 
exon 22 (E22) exclusion in DM1 cells (in comparison to WT cells). Equal levels of cDNA template were confirmed by amplification of the 
GAPDH housekeeping gene. (B) Western blot analysis for CLCN1 skeletal muscle-specific chloride channel expression in immortalized WT 
and DM1 cell lines. -actin protein expression was used as a loading control. HTS-Compatible Splicing Assay in DM1 Cells  Current Chemical Genomics, 2010, Volume 4    15 
the minigene reporter construct expressed as expected. Com-
plete intron 2 retention was found in 43±1%, 63±1% and 
72±2% of CLCN1-luc transcripts in DM1 fibroblasts, 
myoblasts and myotubes, respectively (versus 2.4±1%, 
3.5±1% and 5±1% in WT counterparts), and partial intron 2 
retention was seen at similar levels (14±2%) in CLCN1-luc 
transcripts of both WT and DM1 cells, in agreement with a 
previously identified cryptic splice site in CLCN1 intron 2 
[29]. Identity of all RT-PCR products was confirmed by se-
quencing. 
  Since aberrant splicing patterns of MBNL1/CUGBP1 
target genes were observed in both immortalized DM1 
myoblasts and myotubes, further HTS assay development 
was limited to myoblasts, as this allowed for easier propaga-
tion of cells, shorter incubation times prior to luciferase 
readout, and was not complicated by the heterogeneity of 
myotube differentiation stage between wells and across ex-
periments. A panel of protein kinase B (PKB or AKT) and 
protein kinase C (PKC) inhibitors were screened in 384-well 
format for their ability to serve as a positive control by en-
hancing expression of the CLCN1-luc construct in DM1 
myoblasts (data not shown), based on reports that CUGBP1 
activation and phosphorylation is mediated by members of 
these kinase families [51, 56]. From these experiments only 
one compound, an AKT V inhibitor Triciribine (Calbio-
chem), enhanced luciferase expression in DM1 CLCN1-luc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). CLCN1-luc minigene reporter construct splicing and expression in immortalized DM1 cell lines. (A) Schematic of CLCN1 
luciferase minigene reporter (CLCN1-luc). A genomic segment of human CLCN1 containing exon 2 to 3 and the intervening intron (solid 
line) was cloned downstream of the CMV promoter (CMVpr) and in-frame with the luciferase coding sequence in the pLenti6/V5-D-TOPO 
vector. Dotted lines represent correct splicing (as in WT cells). Intron 2 retention (as in DM1 cells) results in a nonsense mutation, as indi-
cated by TGA. (B) RT-PCR analysis with primers spanning CLCN1 exon 2 to the luciferase coding region, demonstrating complete (+ intron 
2) and partial (+ partial intron 2) intron 2 retention of the CLCN1-luc construct in immortalized DM1 cells compared to WT cells (- intron 2), 
which was partially rescued upon treatment of CLCN1-luc DM1 myoblasts with 10 μM AKT inhibitor Triciribine (C). GAPDH was ampli-
fied as a control for equivalent cDNA synthesis. (D) CLCN1-luc activity (RLU = relative luciferase units) 24 h after addition of 10 μM 
Triciribine to CLCN1-luc WT and DM1 myoblasts (in 384-well format). *** represents a p-value = 1.1 x 10
-5 and * represents a p-value = 
2.4 x 10
-3 in two-tailed t-tests. Data points are an average of 3 replicates and error bars represent standard deviation.  16    Current Chemical Genomics, 2010, Volume 4  O’Leary et al. 
myoblasts by 5.3±0.4 fold 24 h after compound addition (p = 
1.1 x 10
-5 in a two-tailed t-test) (Fig. 4D), and RT-PCR 
analysis confirmed that this was due to partial restoration of 
CLCN1-luc splicing in treated DM1 cells (Fig. 4C). Treat-
ment of cells with DMSO alone enhanced CLCN1-luc splic-
ing in DM1 myoblasts, and was presumed to act by making 
RNA more accessible to general splicing factors. The splic-
ing of CLCN1-luc was further improved following treatment 
of DM1 CLCN1-luc myoblasts with Triciribine; only 8±1% 
of transcripts contained intron 2 following Triciribine treat-
ment (versus 19±2% in DMSO treated cells), and 59±2% of 
transcripts lacked intron 2 completely. Triciribine only gave 
a 1.2±0.2 fold increase in luciferase signal in CLCN1-luc 
WT myoblasts compared to DMSO treatment (p = 2.4 x 10
-
3), but this was not surprising given that these cells already 
spliced the reporter construct correctly. Given its reproduci-
ble effect on the CLCN1-luc construct in DM1 myoblasts, 
Triciribine was used as a positive control for miniaturization 
of the CLCN1-luc DM1 myoblast reporter gene assay into 
1536-well format and assay validation for HTS.  
Assay Miniaturization and HTS Validation of CLCN1-
luc DM1 Myoblasts 
  The CLCN1-luc assay in DM1 myoblasts was miniatur-
ized from a 50 μl cell plating volume in 384-well format to a 
6 μl volume in 1536-well format. The health of the CLCN1-
luc DM1 myoblasts was maintained with a final DMSO con-
centration up to 1% in both 384-well and 1536-well formats 
(as determined by alamarBlue® (BioSource™), data not 
shown), and 0.83% DMSO (50 nl into 6 μl) was used for the 
HTS validation study. As shown in Fig. (5A), miniaturiza-
tion of the assay lead to a slight decrease in assay window; 
5.3 fold increase in signal upon Triciribine treatment in 384-
well format and 4.3 fold increase in 1536-well format. For 
ease of comparison with test compounds and to prevent cel-
lular toxicity, a final concentration of 8.3 μM Triciribine was 
used as a positive control on all 1536-well assay plates dur-
ing the HTS validation, which was the same concentration as 
the compounds screened.  
  The robustness of the CLCN1-luc assay was tested by 
performing a validation HTS of ~13,000 small molecule 
compounds in triplicate in 1536-well format. Fig. (5B) de-
picts the trace of plate median relative activity for test com-
pound wells, as well as DMSO and Triciribine control wells, 
and shows maintenance of an assay window of 4-fold 
throughout the screen, with a Z´ factor = 0.5 and CV = 9%. 
Thus the CLCN1-luc assay was deemed amenable to HTS. 
By plotting a histogram of relative activity of test com-
pounds (Fig. 5C) a normal distribution with mean = 1.0 was 
observed and a hit rate of 0.26% was observed using a 
threshold of greater than 1.3 fold increase in CLCN1-luc 
signal above that of the DMSO negative control. The repro-
ducibility of hits was 29.8%, and may be improved in future 
studies by raising the threshold for hit determination. 
CONCLUSION 
  We have generated an immortalized DM1 (DMPK 
CTG1000) fibroblast cell line that is easily induced to differen-
tiate into myoblasts, and retains DM1 phenotypic character-
istics including defective differentiation into myotubes, 
MBNL1 co-localization with CUGexp transcripts in nuclear 
foci, and mis-splicing of MBNL1/CUGBP1 target genes. In 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). CLCN1-luc assay miniaturization and HTS validation in immortalized DM1 myoblasts. (A) CLCN1-luc DM1 myoblasts were 
treated with 10 μM Triciribine for 24 h prior to luciferase activity readout (RLU = relative luciferase units) in 384-well and 1536-well for-
mats. Data points are an average of 3 (384-well) or 6 (1536-well) replicates, and error bars represent standard deviation. (B) Activity trace of 
HTS of ~13,000 compounds (in triplicate) against CLCN1-luc in DM1 myoblasts in 1536-well format, showing plate median values of 
DMSO negative control wells (blue), Triciribine positive control wells (red), and test compounds (green), expressed as fold change relative 
to DMSO. An assay window of 4-fold was maintained throughout the screen (CV = 9% and Z´ factor = 0.5). (C) Histogram of normalized 
luciferase expression data (green) from HTS of ~13,000 compounds, indicating threshold of >1.3 fold change (relative to DMSO) used to 
determine a hit rate of 0.26%. Red indicates 10x activity. HTS-Compatible Splicing Assay in DM1 Cells  Current Chemical Genomics, 2010, Volume 4    17 
addition, we have developed the CLCN1-luc luciferase-
based minigene reporter assay that monitors aberrant splic-
ing of CLCN1 and shows the expected increase in intron 2 
retention in immortalized DM1 myoblasts in comparison to 
WT cells. The CLCN1-luc assay in DM1 (DMPK CTG1000) 
myoblasts was successfully miniaturized into 1536-well 
format and shown to be robust enough for HTS, and the 
AKT inhibitor Triciribine was identified as a useful tool 
compound that partially restores CLCN1  splicing in DM1 
cells. The CLCN1-luc construct was also stably introduced 
into WT (DMPK CTG5) and DM1 (DMPK CTG50) fibro-
blasts, in an identical manner to the DM1 (DMPK CTG1000) 
cell line, generating additional tools for triaging hits accord-
ing to their dependence upon CTG repeat length. Thus we 
have developed an ideal system for conducting HTS to better 
understand and treat DM1, a complex multi-systemic genetic 
disease.  
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